Rahul Kakkar, MD

President and CEO of Tome Biosciences

Rahul is a biotech executive and physician-scientist, founding and building biotechnology companies as well as working as a practicing physician. He also serves as an Entrepreneur Partner at Polaris Partners. Most recently, Rahul was Chief Executive Officer at Pandion Therapeutics, a company focused on therapeutics for autoimmune and inflammatory diseases, which he led from Series A through its initial public offering and ultimate acquisition by Merck for $1.85B. Prior to joining Pandion, Rahul founded Corvidia Therapeutics, a precision cardiovascular company, where he served as Chief Medical Officer and Chief Strategy Officer. Corvidia Therapeutics was acquired by Novo Nordisk for $2.1B. Prior to Corvidia, Rahul served as a director in the Emerging Innovations Unit at AstraZeneca. Rahul practices cardiovascular medicine at the Brigham and Women’s Hospital in Boston and is a lecturer in medicine at Harvard Medical School. Rahul received his BA from Tufts University and MD from the Tufts University School of Medicine.